Targets Validation for Bladder Cancer
Drug targets and modes of action remain two of the biggest challenges in modern drug discovery and development. At Alfa Cytology, we have established a comprehensive platform to support the target validation of bladder cancer targets in different therapeutic areas.
Introduction to Targets Validation for Bladder Cancer
Target identification (identifying the correct drug target for a disease) and target validation (demonstrating the effect of target perturbation on disease biomarkers and disease endpoints) are important steps in drug development. Target validation is a critical step in the discovery of new drugs for bladder cancer, and this important process involves the application of a range of techniques to demonstrate that a drug works against its target. The spectrum of target validation techniques is summarized below:
Fig 1. Techniques for target validation.
Early and comprehensive target validation helps to establish a clear link between target manipulation and disease efficacy, thereby significantly increasing the chances of trial success. Once the target reaches an acceptable level of validation and disease association, the programme moves to the hit identification phase.
Our Services
Relying on high-resolution mass spectrometry platform, combined with affinity chromatography and active-site directed probe technology, Alfa Cytology has developed and validated a variety of small molecule target identification platforms. Our target-based small molecule drug target identification solutions include:
- Functional Analysis
We offer a variety of techniques to assist our clients in functional analysis, including gene knockout, antisense technology, and RNAi screening. These approaches allow our customers to manipulate target genes and study their impact on cell behavior and morphology.
- Expression Profiling
Microarrays: Allows the simultaneous detection of thousands of genes and provides a snapshot of gene expression patterns within a sample.
RNA-Seq: Offers a comprehensive and quantitative analysis of the entire transcriptome.
qPCR: A sensitive and specific method used to quantify the expression of selected genes.
NanoString Technology: Direct measurement of individual RNA molecules.
scRNA-Seq: Provides a detailed view of gene expression at the single-cell level.
- Cell-Based Assays
We provide human primary in vitro studies using single cells, multicellular, co-culture, and 3D spheroid platforms are used to monitor cell viability, cell proliferation, cell exhaustion, cell translocation, cytokine response, biochemical function, and mechanism of action (MOA), as well as other phenotypic changes.
- In Vivo Target Validation
We provide in vivo target validation which is necessary to evaluate the relevance of a particular target for the bladder cancer in appropriate animal models using suitable biological tools. Multiple preclinical disease models are available at Alfa Cytology to mimic the systemic implications of disease and can provide early in vivo key data for drug targets.
- Reporter Gene Analysis
We offer a range of reporter gene analyses for real-time measurement of specific in vitro or ex vivo conditions (e.g. tissue hypoxia) or for tracking tumor growth and metastasis.
Contact Us
At Alfa Cytology, we are dedicated to supporting your bladder cancer research and development needs. Our team of experienced scientists and researchers is ready to assist you in every step of your project, from protocol design to project completion. We offer a wide range of products, services, and solutions that can help accelerate your research and facilitate the validation of targets for bladder cancer. If you have any needs, please contact us today.
For research use only. Not intended for any clinical use.
Related Services
